Results 201 to 210 of about 21,696 (215)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Cytokine and Growth Factor Reviews, 2020
Cigir Biray Avci, Bakiye Goker Bagca
exaly  

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Annals of Hematology, 2020
Hu Xiaomei, Xueying Wang, Yujin Li
exaly  

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

Cancer, 2021
Elisabetta Abruzzese, Elena Maria Elli, Giuseppe Auteri   +2 more
exaly  

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2020
Elisabetta Abruzzese, Nicola Sgherza, Elena Maria Elli   +2 more
exaly  

Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis

Drugs, 2015
Greg L Plosker
exaly  

Coccidioidomycosis in Patients Treated With Ruxolitinib.

Open Forum Infectious Diseases, 2020
Yael Kusne, Janis E Blair
exaly  

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

Blood, 2013
Dominik Wolf, Annkristin Heine, Christian Kurts   +2 more
exaly  

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis Free

Blood, 2013
Haifa Kathrin Al-Ali, Alessandro Maria Vannucchi, Francesco Passamonti   +2 more
exaly  

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Annals of Hematology, 2017
Savan Shāh, Rami S Komrokji, Chetasi Talati   +2 more
exaly  

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Blood, 2012
Mario Cazzola, Francesco Passamonti, Zeev Estrov   +2 more
exaly